Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 10,880 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 44 more

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 266
States / cities: Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 200 more

Conditions: Hypertension
Interventions: placebo, PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Los Angeles, California • Santa Ana, California • Tustin, California + 15 more

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: Asthma, Diabetes Mellitus
Interventions: Inhaled Insulin, Subcutaneous Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 86
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more

Conditions: HIV Infections
Interventions: Stable CH505TF gp120, Transient CH505TF gp120, Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Neoplasms, Breast
Interventions: lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Scottsdale, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 5 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
Interventions: Cool-Cap; Device
Lead sponsor: Olympic Medical; Industry
Eligibility: 1 Hour to 6 Hours
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 19
States / cities: Little Rock, Arkansas • Oakland, California • San Diego, California + 15 more

Conditions: Solid Tumors
Interventions: Bemarituzumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Duarte, California • Orange, California • Aurora, Colorado + 7 more

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Interventions: Device; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1983 – 2040
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 111 more

Conditions: Open tíbia Fracture, Osteomyelitis Tibia, Tibial Fractures
Interventions: Vancomycin Hydrochloride, Gentamicin, Standard Intramedullary Nail; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Macon, Georgia • Chicago, Illinois + 9 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma
Interventions: CDX-3379 and cetuximab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 7 more

Conditions: Female Sexual Arousal Disorder
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 51
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Memantine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Head and Neck Cancer
Interventions: e-learning didactic module, Personal reflection activities; Behavioral
Lead sponsor: Bethany Rhoten; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Interventions: Collection of Biological Samples, Symptom and Exposure Surveys; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5,599 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Urinary Incontinence
Interventions: Darifenacin, Behavioral therapy; Drug · Behavioral
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Timeline: 2005 – 2006
U.S. locations: 67
States / cities: Birmingham, Alabama • Tucson, Arizona • Culver City, California + 58 more

Conditions: Autism Spectrum Disorder, Depression, Suicidal Ideation, Self Esteem
Interventions: Autism-adapted Group Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 11 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions: AZD5991, AZD5991 + Venetoclax; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Orange, California • Aurora, Colorado • Atlanta, Georgia + 7 more

Conditions: Asthma in Children, Allergy
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Detroit, Michigan • St Louis, Missouri • Nashville, Tennessee + 1 more

Conditions: Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Clofazimine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1995
U.S. locations: 17
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 13 more

Search by objective public record fields.

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

CoolCap Trial, Treatment of Perinatal Hypoxic-Ischemic Encephalopathy

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Intramedullary Calcium Sulfate Antibiotic Depot

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Body Image After Head and Neck Cancer Treatment

COVID-19: Human Epidemiology and Response to SARS-CoV-2

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Group Depression Treatment for Autistic Youth

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Childhood Allergy and the Neonatal Environment

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS